Aridhia Sets Its Sights On Us Market With Craneware Partnership
News Mar 10, 2015
Aridhia Informatics, the Edinburgh-based health informatics company, has announced a strategic partnership with fellow Scottish health tech pioneer Craneware as it targets the US market for the first time.
The partnership will enable Aridhia, which has healthcare clients throughout the UK, Australia and Kuwait, to offer its core services – collaborative analytics platform, data science services and app development capability – to Craneware’s extensive US client base. It represents a major opportunity for both parties to work together to help US healthcare organisations benefit from the acceleration and commercialisation of informatics solutions that focus on patient outcomes. A growing number of medical insurers are moving away from fee-for-service towards performance-based reimbursement and this is driving the requirement for informatics solutions.
David Sibbald, CEO of Aridhia, said: “US healthcare providers have traditionally focused on financial outcomes and cutting costs but they are increasingly adopting a patient centric approach which will, in turn, have a positive effect on their bottom line. Craneware works with some of the biggest healthcare providers in the US so we’re very pleased to be partnering with them and using our integrated healthcare informatics services to deliver better operational results for the Craneware customer, hospitals and therefore, better health outcomes for their patients.”
Craneware is a market leader in automated revenue integrity solutions that improve financial performance for healthcare organisations. During the last 15 years, one quarter of all registered US hospitals have chosen Craneware’s medical billing software solutions to assist them on their journey to improved financial performance and revenue integrity.
AIM listed, Craneware is headquartered in Edinburgh with offices across the US. The company employs over 200 people and its development activity is based in Scotland.
Clients using Craneware’s innovative SaaS (Software as a Service) solutions range from small community hospitals to large healthcare networks, and include leading organisations such as Intermountain Healthcare, The Cleveland Clinic, and The John Hopkins Hospital.
Keith Neilson, Craneware CEO, said: “We are pleased to bring Aridhia’s AnalytiXagility platform to our client base, offering Aridhia's expertise in utilising our clients' data to improve their patient outcomes."
Aridhia’s collaborative analytics platform and safe haven, AnalytiXagility, underpins the world-leading Stratified Medicine Scotland Innovation Centre (SMS-IC). In addition, AnalytiXagility and its supporting data science and application development services are being deployed in healthcare use cases that include: analysing waveform data from traumatic brain injured patients, implementing risk stratification to reduce hospital readmissions, building population level diabetes risk models, predicting the disease pathway of multiple sclerosis patients based on imaging data, and underpinning Horizon 2020 research programmes that include smart ageing, cystic fibrosis and cancer biomarkers related data.
Computer Program Helps Find Ways to Repurpose Existing DrugsNews
Researchers have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy.READ MORE
Big Data From Social Media Helps Combat Prescription Drug CrisisNews
Researchers have conducted a critical review of existing literature to determine whether social media big data can be used to understand communication and behavioral patterns related to prescription drug abuse.READ MORE
Machine Learning: Helping Determine How a Drug Affects the BrainNews
Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published today in Brain.READ MORE